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Objectives: We tested a previously published model for the analysis of the temporal relationship
between antibiotic use and the incidence of Clostridium difficile infection in a hospital with stable inci-
dence of infection at >1 case per 1000 admissions per month.
Methods: The study period was from April 2004 to June 2008 and used data from Infection Control and
Hospital Pharmacy. We first described the monthly variation in C. difficile infection and then con-
structed a multivariate transfer function model that included lag time (cases of C. difficile infection in
previous months and delays between changes in antibiotic use and changes in C. difficile infection).
Results: The average incidence of C. difficile infection was 1.5 cases per 1000 patients per month with
no significant increase over 3 years. The number of cases of C. difficile infection in 1 month was
dependent on the average number of cases of C. difficile infection in the previous 2 months. The
models with data from the whole hospital showed a statistically significant relationship between the
number of both hospital-acquired C. difficile infections and total C. difficile infections and consump-
tion of piperacillin/tazobactam, ciprofloxacin and cefuroxime. The association between C. difficile
infection and consumption of co-amoxiclav was only significant for hospital-acquired C. difficile infec-
tion. The model for hospital-acquired C. difficile infections explained 61% of the variance in C. difficile
infections.
Conclusions: These results provide support for antibiotic policies that minimize the use of broad-spec-
trum penicillins (co-amoxiclav and piperacillin/tazobactam), cephalosporins and fluoroquinolones.
Keywords: time series analysis, hospital-acquired infections, piperacillin/tazobactam, cephalosporins,
fluoroquinolones, co-amoxiclav
Introduction
The aim of this study was to apply a model for time series
analysis of the temporal relationship between antibiotic use and
the incidence of Clostridium difficile infection in a hospital with
stable incidence of infection at .1 case per 1000 admissions per
month. The model was developed and tested in Geneva, where
the average incidence of infections over 6 years was ,0.27
cases per 1000 admissions per month, ranging from 0.04 to 0.54
cases per 1000 admissions per month.1 In Geneva, a transfer
function model that included all antibiotic use and alcohol-based
hand rubs only explained 17% of variation in C. difficile
infections, and the use of broad-spectrum cephalosporins was
the only statistically significant explanatory variable.1 Our
hypothesis was that stronger relationships between C. difficile
infection and antibiotic use would be present in a hospital with
a higher incidence of C. difficile infection.
A common error in the statistical analysis of time series is to
assume that one observation in a data set is independent from
the other observations. This is often not true in a time series,
especially when the observations are cases of infection. It is
very likely that the number of cases of C. difficile in a ward in
1 month is influenced by the number of cases in previous
months, so these observations are dependent on one another.
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One of the key steps in the statistical analysis of a time series
will therefore be to extract this structure and transform the initial
time series into a series of independent values.
Methods
Data collection
Ninewells Hospital is a University Hospital with 879 beds; there
were 51498 inpatient admissions and 16412 day cases in 2004.2 The
hospital has full specialist services with the exception of
cardiothoracic surgery and organ transplantation. The data about
C. difficile infections were provided from the Infection Control data-
base in the Department of Medical Microbiology at Ninewells
Hospital and the data about antibiotic use were provided by the
Pharmacy Department, extracted with Business Objects from the
Ascribe database. The study period was from April 2004 to June
2008. For statistical analysis, we first described the monthly variation
in C. difficile infection and then constructed a multivariate transfer
function model that included lag time (cases of C. difficile infection
in previous months and delays between changes in antibiotic use and
changes in C. difficile infection). The model has been described in
detail previously.1 Monthly antibiotic use was expressed in the
WHO’s recommended metric, the defined daily dose.3 A P value of
,0.05 was considered to be statistically significant.
Ethics approval was not required because we only used routine
data aggregated by hospital wards.
Modelling
The main analysis used only C. difficile infections that presented in
the hospital (onset of symptoms .48 h after admission to hospital),
labelled HA_CDIFF. We also repeated all analyses with total cases
of C. difficile (TOT_CDIFF), which includes C. difficile infection
presenting from the community. Data from the Infection Control
team showed that of the 43 C. difficile infections presenting from
the community between February and June 2008, 30 (70%) occurred
in people who had been inpatients within the previous 12 weeks. It
is therefore plausible that hospital antibiotic use has some influence
on the number of C. difficile infections that present in the
community.
Previous point prevalence surveys of antibiotic use at Ninewells
Hospital showed that cefuroxime is mainly used for the treatment of
surgical infections, whereas in medical wards there is very little use
of cefuroxime because co-amoxiclav is the main therapeutic
antibiotic.4 In contrast, in surgical wards most of the co-amoxiclav
use is due to single dose, pre-operative antibiotic prophylaxis.
Fluoroquinolone use was also substantially different between the
Medicine and Cardiovascular wards, where levofloxacin and
moxifloxacin were used to treat respiratory infections, whereas
ciprofloxacin was the only fluoroquinolone that was used signifi-
cantly in other wards. We therefore applied the same models
restricted to data from wards in the Medicine and Cardiovascular
group (HA_CDIFF M&C and TOT_CDIFF M&C) to test the
hypothesis that there would be a stronger association between
C. difficile infections and co-amoxiclav use or fluoroquinolone use
in medical wards than we had seen in the whole hospital.
Statistical methods
Since temporally sequenced observations on antibiotic use and
resistance are not independent, applying simple regression analysis
would be inappropriate.5 We chose an autoregressive integrated
moving average (ARIMA) model with the Box–Jenkins method,
which allows for the stochastic dependence of consecutive data over
time.5 This method estimates the dependence between observations
over time and relaxes the assumption of independent observations,
which lessens a common threat to valid inferences.6 The major
limitation regarding the use of this approach is that it has large data
requirements.6 The recommended minimum is 50 timepoints. We
used 51 monthly timepoints from April 2004 to June 2008.
We used linear transfer function modelling to quantify the
dynamic relationship between the use of several antibiotics and the
incidence of C. difficile infections, taking into account delays of up
to 5 months in effect.1,7 For each individual series, we identified and
fitted an ARIMA model according to the Box–Jenkins method.5
First, we checked if the series were stationary with the augmented
Dickey–Fuller test; we accepted changes of ,10% in mean and var-
iance as stationary. Second, we determined the ARIMA model
orders with the autocorrelation and partial autocorrelation functions.
Third, we estimated model parameters by the unconditional least
squares method. Finally, we checked the adequacy of the model and
eliminated irrelevant variables with the Ljung–Box statistic at a
P value of ,0.05. The generated coefficient R2 measures the overall
fit of the regression line, expressing how close the points are to the
estimated regression line in the scatter plot. In other terms, R2 is
the fraction of the variance of the dependent variable explained by
the regression.
All statistical analyses were performed with EViews 6 software
(QMS, Irvine, CA, USA).
Results
C. difficile infections
There were between 10 and 36 cases of C. difficile infection per
month over the 3 year study period with an average incidence of
1.5 cases per 1000 patients per month (Figure 1). There was a
non-significant upward trend in HA_CDIFF (P¼0.0932), a sig-
nificant upward trend in TOT_CDIFF (P¼0.0309) and a non-
significant upward trend in HA_CDIFF M&C (P¼0.9054) and
TOT_CDIFF M&C (P¼0.5336).
All the time series analyses have a moving average order of
2, meaning that the number of cases of C. difficile infection
in 1 month is dependent on the average number of cases of
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Figure 1. Transfer function model for C. difficile infections; Ninewells
Hospital April 2004 to June 2008.
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C. difficile infection in the previous 2 months. By including this
moving average in the model, we transformed the original time
series of C. difficile infections into independent values that can
be analysed with standard statistical tests.
Modelling
In the models with data from the whole hospital, we found a
statistically significant relationship between the number of both
hospital-acquired C. difficile infections and total C. difficile
infections and consumption of piperacillin/tazobactam, cipro-
floxacin and cefuroxime (Table 1). The association between
C. difficile infection and consumption of co-amoxiclav was only
significant for hospital-acquired C. difficile infections (Table 1).
The model for hospital-acquired C. difficile infections explained
61% of the variance in C. difficile infections over time, whereas
the model for total C. difficile infections only explained 49% of
the variance (Table 1).
In the models with data from the Medicine and Cardiovascular
wards, we found a statistically significant relationship between
the number of both hospital-acquired C. difficile infections and
total C. difficile infections and consumption of piperacillin/tazo-
bactam, co-amoxiclav and fluoroquinolones (Table 1). The
association between C. difficile infection and consumption of cef-
triaxone was only significant for total C. difficile infection
(Table 1). The model for hospital-acquired C. difficile infections
explained 53% of the variance in C. difficile infections over time
and the model for total C. difficile infections explained 56% of
the variance (Table 1).
Graphical presentation shows a close relationship between the
observed number of monthly C. difficile infections and the
number predicted by the transfer function model. The residual
was ,10 C. difficile infections in any month (Figure 1).
Supplementary data regarding the modelling results with
additional charts are available at JAC Online (http://
jac.oxfordjournals.org).
Discussion
Our analysis shows a strong relationship between variation in
antibiotic use and variation in C. difficile infections (Table 1).
A weakness of our data is that we did not have data about
individual patient exposure to antibiotics and our analysis is
therefore subject to ecological bias. However, in general, eco-
logical bias weakens the association between exposure and
outcome.8
Overall, these results provide support for antibiotic policies
that minimize the use of broad-spectrum penicillins
(co-amoxiclav and piperacillin/tazobactam), cephalosporins and
fluoroquinolones. The differences between the results for the
whole hospital versus the Medicine and Cardiovascular wards
were expected because of the recommendations of the Hospital
Antibiotic Policy at the time and the results of previous point
prevalence surveys (see the Modelling sub-section in the
Methods section). We also expected minor differences between
the results of analyses that used only HA_CDIFF versus
TOT_CDIFF because we have found that most cases of
C. difficile infection presenting from the community had been
hospitalized within the previous 12 weeks, as has been reported
from other hospitals.9,10 A substantial proportion of the cef-
triaxone use by Medicine and Cardiovascular wards is for out-
patient or home parenteral therapy.11 This probably explains
why ceftriaxone use in these wards was associated with total
Table 1. Transfer function model for C. difficile infections; Ninewells Hospital April 2004 to June 2008
Lag time
(months)
Ninewells
HA_CDIFF
Ninewells
TOT_CDIFF
Medicine and Cardiovascular
ward level
HA_CDIFF M&C
Medicine and Cardiovascular
ward level
TOT_CDIFF M&C
Piperacillin/tazobactam 4 0.05014*
5 0.091559* 0.092976* 0.054005**
Co-amoxiclav 0 0.002732* 0.005096** 0.010654*
Ciprofloxacin 0 0.007828*
5 0.003976*
Fluoroquinolonesa 4 0.011412* 0.007004**
Cefuroxime 2 0.005655**
3 0.005535* 0.003399**
4 0.006130*
Ceftriaxone 2 0.014068**
3 0.023926*
Moving average order 2 0.963635* 0.953730* 1.2379* 0.957879*
Overall fitting 61.35% 48.66% 53.45% 55.65%
aCiprofloxacin, levofloxacin and moxifloxacin.
*Statistically significant at P value ,1%.
**Statistically significant at P value ,5%.
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rather than hospital-acquired C. difficile infections. There are
several plausible explanations for a lag in the association
between antibiotic use and C. difficile infections. First, there is
a delay between drug supply to the wards and consumption by
patients. Second, the link between antibiotic consumption and
C. difficile infection has several steps (environmental contami-
nation, colonization of patients, exposure to antibiotics, symp-
tomatic infection and diagnosis), each of which can add
further delay.
We expected that C. difficile infection would be associated
with the use of cephalosporins, fluoroquinolones and
co-amoxiclav.12 In a meta-analysis, co-amoxiclav had the third
highest pooled odds ratio for increased risk of C. difficile infec-
tion after cefotaxime and ceftazidime.12 However, we were sur-
prised that variation in piperacillin/tazobactam was so strongly
associated with C. difficile infections in our model because
replacement of third-generation cephalosporin use by piperacil-
lin/tazobactam has been associated with sustained reduction in
C. difficile infections.13 It has been proposed that piperacillin/
tazobactam is less likely to be associated with C. difficile infec-
tions because it inhibits growth of C. difficile and because it
stimulates less toxin production than cefotaxime.12,14 However,
b-lactam plus b-lactamase inhibitor combinations have been
associated with C. difficile infections, even in studies of single
dose use for surgical prophylaxis.15
These data were critical in supporting the Antimicrobial
Management Team at Ninewells Hospital with the imple-
mentation of a new antibiotic policy that limits the use of
cephalosporins, co-amoxiclav and fluoroquinolones. These rec-
ommendations are part of the national Scottish Antimicrobial
Prescribing guidelines on antimicrobial measures to reduce
C. difficile-associated disease.16 Use of piperacillin/tazobactam
was already restricted by an Alert Antibiotic Policy but the
results of the model have reminded clinicians that it is plaus-
ible that use of any broad-spectrum antibiotic will increase the
risk of C. difficile infection.12 Modelling drug use by perform-
ing a time series analysis is a useful tool for decision-makers
and complements traditional surveillance and epidemiological
analyses.
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